TEVA-SALBUTAMOL STERINEBS P.F. SOLUTION

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

SALBUTAMOL (SALBUTAMOL SULFATE)

제공처:

TEVA CANADA LIMITED

ATC 코드:

R03AC02

INN (International Name):

SALBUTAMOL

복용량:

1MG

약제 형태:

SOLUTION

구성:

SALBUTAMOL (SALBUTAMOL SULFATE) 1MG

관리 경로:

INHALATION

패키지 단위:

20(2.5ML UNIT DOSES)

처방전 유형:

Prescription

치료 영역:

SELECTIVE BETA 2-ADRENERGIC AGONISTS

제품 요약:

Active ingredient group (AIG) number: 0108887007; AHFS:

승인 상태:

APPROVED

승인 날짜:

2012-07-05

제품 특성 요약

PRODUCT MONOGRAPH
PR
TEVA-SALBUTAMOL STERINEBS
TM P.F.
Salbutamol Sulphate Solution
1 mg / mL (2.5 mg / 2.5 mL) salbutamol per ampoule
2 mg / mL (5 mg / 2.5 mL) salbutamol per ampoule
Bronchodilator
(beta
2
-adrenergic agonist)
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Canada
www.tevacanada.com
Submission Control No: 254982
Date of Revision::
Dec. 21, 2021
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY
PRODUCT
INFORMATION
.............................................................................
3
INDICATIONS
AND
CLINICAL
USE
......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
3
WARNINGS
AND
PRECAUTIONS
..........................................................................................
4
ADVERSE
REACTIONS
...........................................................................................................
7
DRUG
INTERACTIONS
............................................................................................................
9
DOSAGE
AND
ADMINISTRATION
......................................................................................
10
OVERDOSAGE
........................................................................................................................
12
ACTION
AND
CLINICAL
PHARMACOLOGY
.....................................................................
12
STORAGE
AND
STABILITY
..................................................................................................
14
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ...................................................... 14
PART II: SCIENTIFIC INFORMATION
...............................................................................
15
PHARMACEUTICAL
INFORMATION..................................................................................
15
CLINICAL
TRIAL